- Conditions
- Anticoagulation Reversal
- Interventions
- PER977, Placebo, Edoxaban
- Drug
- Lead sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 388
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma
- Interventions
- Brivanib Alaninate, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 35
- States / cities
- Aurora, Colorado • New Britain, Connecticut • Chicago, Illinois + 19 more
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Pembrolizumab, Paclitaxel, Capecitabine
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Portland, Oregon
- Conditions
- Traumatic Injury
- Interventions
- BE1116, Placebo
- Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 1,366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 90
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 79 more
- Conditions
- Refractory Germ Cell Tumors Expressing EGRF
- Interventions
- ZD1839 Iressa
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Stroke, Secondary Prevention
- Interventions
- optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 5,390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 110
- States / cities
- Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
- Conditions
- Abnormalities, Blood Coagulation Disorder, Brain Disease, Cerebrovascular Accident, Vascular Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Up to 45 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- Docetaxel, Imatinib Mesylate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Intracranial Hemorrhage, Traumatic, Intracranial Hemorrhage, Spontaneous
- Interventions
- Four Factor Prothrombin Complex Concentrate, Fresh Frozen Plasma
- Drug · Biological
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Endometrial Carcinoma
- Interventions
- Arsenic trioxide
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Bintrafusp alfa
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Newark, Delaware • Jacksonville, Florida • Silver Spring, Maryland + 12 more
- Conditions
- Dry Eye Disease
- Interventions
- rhNGF 5 μg/mL, rhNGF 10 μg/mL, Vehicle (Placebo solution)
- Drug
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 10
- States / cities
- Chandler, Arizona • Torrance, California • Colorado Springs, Colorado + 7 more
- Conditions
- Breast Cancer, Breast Neoplasms
- Interventions
- Adriamycin, cyclophosphamide, G-CSF, paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arterial Occlusive Disease, Peripheral Vascular Disease, Ischemia, Ulcers
- Interventions
- HGF plasmid, Placebo
- Genetic
- Lead sponsor
- AnGes USA, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 4
- States / cities
- Pensacola, Florida • Indianapolis, Indiana • Boston, Massachusetts + 1 more
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Opioid Growth Factor
- Biological
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
- Interventions
- Fulvestrant, Repotrectinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Neuroblastoma
- Interventions
- monoclonal antibody 3F8, sargramostim
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Gastric Cancer
- Interventions
- Placebo, Onartuzumab (MetMAb), Oxaliplatin, Folinic acid, Levofolinic acid, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 15 more
- Conditions
- HER2-positive Breast Cancer
- Interventions
- RO7771950, Tucatinib, Trastuzumab, Capecitabine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • San Francisco, California + 10 more
- Conditions
- Venous Thromboembolism
- Interventions
- vMetrics protocol
- Other
- Lead sponsor
- ZIN Technologies, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV Infections, Peripheral Nervous System Disease
- Interventions
- Nerve Growth Factor, Recombinant Human
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Mateo, California • Stanford, California + 10 more
- Conditions
- Hemophilia B
- Interventions
- rIX-FP
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years to 65 Years · Male only
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Chronic Granulomatous Disease, Crohn'S-like IBD, Inflammatory Bowel Disease (IBD)
- Interventions
- Infliximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 10 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acquired Thrombotic Thrombocytopenic Purpura
- Interventions
- Caplacizumab, Placebo
- Biological
- Lead sponsor
- Ablynx, a Sanofi company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more